tirzepatide insurance approval Mounjaro vs. Zepbound: The Same Drug, for Different Purposes Zepbound (Tirzepatide) for Chronic Weight

In the SURMOUNT-4 trial published in the New England Journal of Medicine, participants who switched from tirzepatide to placebo regained approximately two-thirds of their lost weight over the subsequent 52 weeks, while those continuing treatment maintained their weight loss and achieved additional reductions

Local manufacturing initiatives and regional pricing models improve accessibility to GLP-1 therapies

Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial

On a side note: It is essential to keep in mind that Ozempic (Semaglutide) 4 mg/3 ml should not be used in patients under the age of 18 or patients with type 1 diabetes mellitus